Banner - NPPA Connect

NP/PA Connect
News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

|Videos|August 6, 2021

FDA Delays Impacting Inflammatory Skin Disease Community

Author(s)Morgan Petronelli

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

ED Treatment Gaps Persist for Pediatric Atopic Dermatitis

ByChristopher G. Bunick, MD, PhD,Shannon Heaning, Content Associate

July 18th 2026

Scalp psoriasis | Image credit: © DermNet

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

ByKaitlyn Bader, Assistant Managing Editor

July 16th 2026

Precision Medicine in Atopic Dermatitis: Current Challenges and Future Directions

ByChristopher G. Bunick, MD, PhD,Shannon Heaning, Content Associate

July 15th 2026

Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD

ByMarie Bosslett, Assistant Editor

July 15th 2026

Phase 2 Trial Supports Oral VDPHL01 for Female Pattern Hair Loss

ByShannon Heaning, Content Associate

July 15th 2026

Latest CME

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Trending on Dermatology Times

Social Media Mythbusters: The Summer Skin Care "Shutdown"

Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites

ED Treatment Gaps Persist for Pediatric Atopic Dermatitis

Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD

Breakout Bulletin: July 13-July 17